Utilizing chitosan nanoparticles for the delivery of biologics to the brain via intranasal route
Source abstract
Abstract
Due to its selective permeability, the blood-brain-barrier presents a major hurdle in brain targeted drug delivery, especially for macromolecules such as proteins or nucleic acids. Nose-to-brain delivery offers a promising opportunity for drug delivery via the olfactory and trigeminal pathway resulting in effective concentrations in the brain tissue and central nervous system when compared to systemic delivery. In this study, polymeric nanoparticles constituted of chitosan, which were further chemically modified and decorated with transferrin as targeting ligand, were utilized to examine the nose-to-brain delivery of proteins. The synthetized chitosan nanoparticles and transferrin decorated chitosan nanoparticles were evaluated for their physicochemical characteristics, release kinetics, cellular uptake and permeability through an epithelial cell layer. The ability of the nanosystem to reach the central nervous system after intranasal administration was assessed using fluorescently labeled nanoparticles containing the model protein β-galactosidase. The results suggest that chitosan nanoparticles can be used for successful delivery of intact proteins to the brain.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (89)
Show source-provided references
1. The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 201710.1016/S2468-2667(20)30190-0 ↗
2. Structure and function of the blood–brain barrier10.1016/j.nbd.2009.07.030 ↗
3. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities10.1016/j.pharmthera.2004.08.001 ↗
4. The blood–brain barrier: structure, regulation and drug delivery10.1038/s41392-023-01481-w ↗
5. Engineering access to the brain: nanotechnologies at the interface of delivery, neurology, and immunotherapy10.1007/s13346-025-02043-z ↗
6. Overcoming the blood–brain barrier: the role of nanomaterials in treating neurological diseases10.1002/adma.201801362 ↗
7. Evolving drug delivery strategies to overcome the blood brain barrier10.2174/1381612822666151221150733 ↗
8. From adsorption to covalent bonding: apolipoprotein E functionalization of polymeric nanoparticles for drug delivery across the blood–brain barrier10.1002/adtp.202000092 ↗
9. Nose-to-brain delivery of biologics10.4155/tde-2019-0013 ↗
10. Intranasal drug delivery to the brain
11. Nasal drug administration: potential for targeted central nervous System delivery10.1002/jps.20318 ↗
12. Intranasal drug delivery: opportunities and toxicologic challenges during drug development
13. Shortcut approaches to substance delivery into the brain based on intranasal administration using nanodelivery strategies for insulin10.3390/molecules25215188 ↗
14. Anatomy, physiology and function of the nasal cavities in health and disease10.1016/S0169-409X(97)00058-6 ↗
15. Sniffing neuropeptides: a transnasal approach to the human brain10.1038/nn0602-849 ↗
16. Intranasal delivery of biologics to the central nervous system10.1016/j.addr.2011.11.002 ↗
17. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype10.1016/j.neurobiolaging.2005.03.016 ↗
18. Insights into direct nose to brain delivery: current status and future perspective10.3109/10717544.2013.838713 ↗
19. In vitro anatomical models for nasal drug delivery10.3390/pharmaceutics14071353 ↗
20. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues10.1016/j.addr.2008.11.002 ↗
21. Nanotherapeutics for nose-to-brain drug delivery: an approach to bypass the blood brain barrier10.3390/pharmaceutics13122049 ↗
22. Using nanotechnology to deliver biomolecules from nose to brain — peptides, proteins, monoclonal antibodies and RNA10.1007/s13346-021-01086-2 ↗
23. Haloperidol-loaded intranasally administered lectin functionalized poly(ethylene glycol)–block-poly(d,l) -lactic-co-glycolic acid (PEG–PLGA) nanoparticles for the treatment of schizophrenia10.1016/j.ejpb.2014.02.007 ↗
24. Chitosan-Based nanocarriers for nose to brain delivery10.3390/app9112219 ↗
25. Chitosan-based drug nanocarriers: where do we stand?10.1016/j.jconrel.2012.03.017 ↗
26. Long‐Term Controlled Release of Simvastatin from Photoprinted Triple‐Networked Hydrogels Composed of Modified Chitosan and PLA–PEG Micelles10.1002/mabi.202100123 ↗
27. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4 ↗
28. Chitosan nanoparticle as protein delivery carrier—Systematic examination of fabrication conditions for efficient loading and release10.1016/j.colsurfb.2007.04.009 ↗
29. Chitosan-modified polymeric nanoparticles for the nose-to-brain drug delivery of paroxetine: an in vitro and in vivo evaluation10.1039/D4NR04250F ↗
30. Lactoferrin-modified rotigotine nanoparticles for enhanced nose-to-brain delivery: lesa-ms/ms-based drug biodistribution, pharmacodynamics, and neuroprotective effects10.2147/IJN.S151475 ↗
31. Usefulness of cell-penetrating peptides and penetration accelerating sequence for nose-to-brain delivery of glucagon-like peptide-210.1016/j.jconrel.2021.06.007 ↗
32. Transferrin receptor antibody-modified α-cobrotoxin-loaded nanoparticles enable drug delivery across the blood–brain barrier by intranasal administration10.1007/s11051-013-2059-6 ↗
33. Nose-to-brain delivery of nanotherapeutics: transport mechanisms and applications
34. Receptor-mediated endocytosis: the intracellular journey of transferrin and its receptor10.1016/S0300-9084(86)80004-9 ↗
35. Transferrin-modified chitosan nanoparticles for targeted nose-to-brain delivery of proteins
36. Encapsulation of lactase (β-galactosidase) into κ-carrageenan-based hydrogel beads: impact of environmental conditions on enzyme activity10.1016/j.foodchem.2016.01.014 ↗
37. Microencapsulation of β-galactosidase with different biopolymers by a spray-drying process10.1016/j.foodres.2014.05.057 ↗
38. The nasal delivery of nanoencapsulated statins - an approach for brain delivery10.2147/IJN.S119033 ↗
39. Live-cell observation of cytosolic HIV-1 assembly onset reveals RNA-interacting Gag oligomers10.1083/jcb.201504006 ↗
40. PAM: a framework for integrated analysis of imaging, Single-Molecule, and ensemble fluorescence data10.1016/j.bpj.2018.02.035 ↗
41. Fluorescence correlation spectroscopy: principles and developments
42. The phasor approach to fluorescence lifetime imaging analysis10.1529/biophysj.107.120154 ↗
43. A multiscale wavelet algorithm for atom tracking in STM movies10.1088/1367-2630/ac4ad5 ↗
44. Particle-based phasor-FLIM-FRET resolves protein-protein interactions inside single viral particles
45. Protein instability in Poly(Lactic-co-Glycolic acid) microparticles. Pharm
46. Nanoparticles for direct nose-to-brain delivery of drugs10.1016/j.ijpharm.2009.06.019 ↗
47. Nose-to-Brain delivery: investigation of the transport of nanoparticles with different surface characteristics and sizes in excised porcine olfactory epithelium. Mol
48. Transferrin decorated thermoresponsive nanogels as magnetic trap devices for circulating tumor cells10.1002/marc.201500590 ↗
49. Transferrin functionalized chitosan-PEG nanoparticles for targeted delivery of paclitaxel to cancer cells10.1016/j.colsurfb.2016.08.059 ↗
50. Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application10.1038/sj.gt.3301351 ↗
51. Bioinspired shielding strategies for nanoparticle drug delivery applications. Mol
52. Microfluidic mixing as platform technology for production of chitosan nanoparticles loaded with different macromolecules10.1016/j.ejpb.2023.05.010 ↗
53. Coming in and finding out: blending receptor-targeted delivery and efficient endosomal escape in a novel bio-responsive siRNA delivery System for gene knockdown in pulmonary T cells
54. Ultrastructure of human nasal mucosa10.1288/00005537-198312000-00011 ↗
55. Mucin structure, aggregation, physiological functions and biomedical applications10.1016/j.cocis.2005.11.001 ↗
56. Mucus composition abnormalities in sinonasal mucosa of chronic rhinosinusitis with and without nasal polyps10.1007/s10753-021-01471-6 ↗
57. Probing the interaction of nanoparticles with mucin for drug delivery applications using dynamic light scattering10.1016/j.ejpb.2015.05.004 ↗
58. The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium10.1080/01926230600713475 ↗
59. Diffusion of macromolecules and virus-like particles in human cervical mucus10.1016/S0006-3495(01)75844-4 ↗
60. Drug transfer through mucus10.1016/S0169-409X(01)00115-6 ↗
61. Hybrid Lipid/Polymer nanoparticles to tackle the cystic fibrosis mucus barrier in siRNA delivery to the lungs: does PEGylation make the difference?10.1021/acsami.1c14975 ↗
62. Chitosan-coated PLGA nanoparticles for the nasal delivery of ropinirole hydrochloride: in vitro and ex vivo evaluation of efficacy and safety10.1016/j.ijpharm.2020.119776 ↗
63. Chitosan and its derivatives for application in mucoadhesive drug delivery systems10.3390/polym10030267 ↗
64. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that “Slip” through the human mucus barrier10.1002/anie.200803526 ↗
65. Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus10.1016/j.biomaterials.2011.05.008 ↗
66. The role of mucus on drug transport and its potential to affect therapeutic outcomes10.1016/j.addr.2017.10.009 ↗
67. Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system10.1016/j.jconrel.2005.11.014 ↗
68. Chitosan/Sodium tripolyphosphate nanoparticles: preparation, characterization and application as drug carrier10.1166/jbn.2009.1067 ↗
69. Overcoming barriers in Pseudomonas aeruginosa lung infections: engineered nanoparticles for local delivery of a cationic antimicrobial peptide10.1016/j.colsurfb.2015.08.027 ↗
70. Development and evaluation of a novel mucus diffusion Test System approved by self-nanoemulsifying drug delivery systems10.1002/jps.23757 ↗
71. The safety of chitosan as a pharmaceutical excipient10.1016/j.yrtph.2009.09.015 ↗
72. Biological safety and biodistribution of chitosan nanoparticles10.3390/nano10040810 ↗
73. Air−Liquid interface cultures of the healthy and diseased human respiratory tract: promises, challenges, and future directions10.1002/anbr.202000111 ↗
74. Chapter 4-Functional anatomy and physiology
75. Treuting · 2017
76. The characterization of the human nasal epithelial cell line RPMI 2650 under different culture conditions and their optimization for an appropriate in vitro nasal model10.1007/s11095-014-1494-0 ↗
77. Targeted drug delivery via the Transferrin receptor-mediated endocytosis pathway10.1124/pr.54.4.561 ↗
78. Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery10.1016/j.addr.2003.07.004 ↗
79. Regarding the amazing choreography of clathrin coats10.1371/journal.pbio.1001037 ↗
80. Strategies to enhance drug absorption via nasal and pulmonary routes10.3390/pharmaceutics11030113 ↗
81. Tight junction modulation by chitosan nanoparticles: Comparison with chitosan solution10.1016/j.ijpharm.2010.08.020 ↗
82. Folate-chitosan nanoparticles triggered insulin cellular uptake and improved in vivo hypoglycemic activity10.1016/j.ijpharm.2019.118708 ↗
83. Cellular uptake of DNA–chitosan nanoparticles: the role of clathrin- and caveolae-mediated pathways10.1016/j.ijbiomac.2012.08.016 ↗
84. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles10.1016/j.jconrel.2009.01.018 ↗
85. Nanocarriers for cytoplasmic delivery: cellular uptake and intracellular fate of Chitosan and hyaluronic acid-coated Chitosan nanoparticles in a phagocytic cell model10.1002/mabi.201100156 ↗
86. Mechanism Study of cellular uptake and tight junction opening mediated by Goblet cell-specific Trimethyl Chitosan nanoparticles10.1021/mp400685v ↗
87. Exploring micellar-based polymeric systems for effective nose-to-brain drug delivery as potential neurotherapeutics
88. Resveratrol anchored nanostructured lipid carrier loaded in situ gel via nasal route: formulation, optimization and in vivo characterization10.1016/j.jddst.2019.01.040 ↗
89. Improved brain pharmacokinetics following intranasal administration of N, N,N-trimethyl chitosan tailored mucoadhesive NLCs10.1080/10667857.2019.1674522 ↗